Skip to main content
SpringerLink
Log in

Dyslipidemia in Obesity

  • Reference work entry
  • First Online:
Metabolic Syndrome

Abstract

Obesity is associated with an increased risk of atherosclerosis and coronary artery disease, in part due to its strong association with atherogenic dyslipidemia. The latter is characterized by elevated plasma triglycerides, low plasma high-density lipoprotein (HDL) cholesterol, and high plasma concentrations of apolipoprotein (apo) B-containing lipoproteins. Dysregulation of lipoprotein metabolism in obese subjects may be due to a combination of overproduction of very-low-density lipoprotein, decreased catabolism of apoB-containing particles, and increased catabolism of HDL particles. These abnormalities may be consequent on a global metabolic effect of insulin resistance and an excess of visceral fat. Lifestyle modifications (dietary restriction and increased physical activity) are first-line therapies to improve lipid abnormalities in obesity. Pharmacological treatments, such as statins, fibrates, ezetimibe, and fish oils, could also be employed alone or in combination with other agents to optimize the benefit of lifestyle modifications on atherogenic dyslipidemia. Kinetic studies show that improvements in lipid and lipoprotein profiles in obesity can be collectively achieved by several mechanisms of action including decreased secretion and increased catabolism of apoB, as well as increased secretion and decreased catabolism of apoA-I. There are several pipeline therapies for correcting atherogenic abnormalities in lipoprotein metabolism. However, their clinical efficacy, safety, and cost-effectiveness remain to be demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low–density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-1236.

    Article  CAS  PubMed  Google Scholar 

  • Alam S, Stolinski M, Pentecost C, et al. The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:688-694.

    Article  CAS  PubMed  Google Scholar 

  • Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.

    Article  CAS  PubMed  Google Scholar 

  • Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004;114:1493-1503.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Angerer P, von Schacky C. n-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol. 2000;11:57-63.

    Article  CAS  PubMed  Google Scholar 

  • Asztalos BF, Horvath KV, McNamara JR, et al. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res. 2002;43:1701-1707.

    Article  CAS  PubMed  Google Scholar 

  • Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-2192.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Bassuk SS, Manson JE. Physical activity and the prevention of cardiovascular disease. Curr Atheroscler Rep. 2003;5:299-307.

    Article  PubMed  Google Scholar 

  • Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf. 1998;19:355-371.

    Article  CAS  PubMed  Google Scholar 

  • Berge J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.

    Article  Google Scholar 

  • Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-1379.

    Article  CAS  PubMed  Google Scholar 

  • Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis. 2011;217:142-148.

    Article  CAS  PubMed  Google Scholar 

  • Brown MS, Goldstein JL. Selective verse total insulin resistance. Cell Metab. 2008;7:95-96.

    Article  CAS  PubMed  Google Scholar 

  • Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.

    Article  CAS  PubMed  Google Scholar 

  • Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.

    Article  CAS  PubMed  Google Scholar 

  • Cannon CP. on behalf of the IMPROVE IT investigators. IMPROVE-IT trial: a comparison of Ezetimibe/Simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014 late-breaking clinical trial abstracts. Circulation. 2014;130:2105-2126.

    Article  Google Scholar 

  • Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF. Apolipoproteins as coronary risk managers: towards a more rationale assessment of dyslipidaemias. QJM. 2006;99:277-287.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Redgrave TG, et al. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 2002a;29:1041-1046.

    Article  CAS  Google Scholar 

  • Chan DC, Watts GF, Barrett PHR, et al. Mechanism of action of an HMG CoA reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab. 2002b;87:2283-2289.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Barrett PHR, et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res. 2002c;43:706-712.

    CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Barrett PHR, et al. Regulatory effects of HMGCoA reductase inhibitor and fish oils on apolipoprotein B100 kinetics with insulin resistant obese male subjects with dyslipidaemia. Diabetes. 2002d;51:2377-2386.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidemia in visceral obesity. Eur J Clin Invest. 2002e;32:429-436.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Nguyen MN, et al. Apolipoproteins C-III and A-V as predictors of VLDL-triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol. 2006a;26:590-596.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Nguyen MN, et al. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and apoA-II in men with abdominal obesity. Am J Clin Nutr. 2006b;84:37-43.

    CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Ng TW, et al. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest. 2008a;38:743-751.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Ooi EMM, et al. Atorvastatin and fenofibrate have comparable effects on VLDL–apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008b;28:1831-1837.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Gan SK, et al. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein–apolipoprotein B-100 in obesity. Arterioscler Thromb Vasc Biol. 2010a;30:1043-1050.

    Article  CAS  PubMed  Google Scholar 

  • Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010b;33:1134-1139.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314-345.

    Article  CAS  PubMed  Google Scholar 

  • Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-156.

    Article  CAS  PubMed  Google Scholar 

  • Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11:563-575.

    Article  CAS  PubMed  Google Scholar 

  • Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-328.

    CAS  PubMed  Google Scholar 

  • Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arterioscler Thromb Vasc Biol. 1990;10:497-511.

    Article  Google Scholar 

  • Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov. 2010;9:267-268.

    Article  CAS  PubMed  Google Scholar 

  • Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl. 2008;9:33-38.

    Article  CAS  PubMed  Google Scholar 

  • Esposito K, Kastorini C-M, Panagiotakos DB, et al. Prevention of type 2 diabetes by dietary patterns: a systematic review of prospective studies and meta-analysis. Metab Syndr Relat Disord. 2010;8:471-476.

    Article  PubMed  Google Scholar 

  • Estruch R, Ros E, Jordi Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290.

    Article  CAS  PubMed  Google Scholar 

  • EUROASPIRE I and II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principle results from EUROASPIRE II Euro Heart Survey. Eur Heart J. 2001;22:554-572.

    Google Scholar 

  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.

    Article  Google Scholar 

  • Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067-3077.

    Article  CAS  PubMed  Google Scholar 

  • Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52:2198-2205.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Forcheron F, Cachefo A, Thevenon S, et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002;51:3486-3491.

    Article  CAS  PubMed  Google Scholar 

  • Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Geneieve M, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.

    Article  Google Scholar 

  • Ginsberg HN. Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91:383-392.

    Article  CAS  PubMed  Google Scholar 

  • Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7:325-331.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein J, Ho Y, Brown M, et al. Cholesteryl ester accumulation in macrophages resulting from receptor- mediated uptake and degradation of hypercholesterolemic canine beta- very low density lipoproteins. J Biol Chem. 1980;255:1839-1848.

    CAS  PubMed  Google Scholar 

  • Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S-1654S.

    CAS  PubMed  Google Scholar 

  • Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-1131.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Jacobson TA. Combination lipid-altering therapy: an emerging treatment paradigm for 21st century. Curr Atheroscler Rep. 2001;3:373-382.

    Article  CAS  PubMed  Google Scholar 

  • James AP, Watts GF, Barrett PH, et al. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism. 2003;52:136-1341.

    Article  CAS  PubMed  Google Scholar 

  • Jorgensen AB et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2012;34:1826.

    Article  PubMed  CAS  Google Scholar 

  • Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002;277:8755-8758.

    Article  CAS  PubMed  Google Scholar 

  • Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000;2:26-46.

    Article  Google Scholar 

  • Kastelein JJ, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.

    Article  CAS  PubMed  Google Scholar 

  • Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19:3124-3131.

    Article  CAS  PubMed  Google Scholar 

  • Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

    Article  CAS  PubMed  Google Scholar 

  • Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.

    Article  CAS  PubMed  Google Scholar 

  • Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483-1492.

    Article  CAS  PubMed  Google Scholar 

  • Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305-311.

    Article  CAS  PubMed  Google Scholar 

  • Lamon-Fava S, Diffenderfer MR, Barrett PHR, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28:1672-1678.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212.

    Article  PubMed  CAS  Google Scholar 

  • Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232.

    Article  CAS  PubMed  Google Scholar 

  • Liang G, Ou J, Bashmakov Y, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14:2819-2830.

    Article  PubMed  Google Scholar 

  • Magkos F, Wright DC, Patterson BW, et al. Lipid metabolism response to a single, prolonged bout of endurance exercise in healthy young men. Am J Physiol Endocrinol Metab. 2006;290:355-362.

    Article  CAS  Google Scholar 

  • Matsumoto M, Han S, Kitamura T, et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116:2464-2472.

    PubMed Central  CAS  PubMed  Google Scholar 

  • McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-23453.

    Article  CAS  PubMed  Google Scholar 

  • Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-2333.

    Article  PubMed  Google Scholar 

  • Naples M, Baker C, Lino M, et al. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1043-G1052.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ng TWK, Watts GF, Barrett PHR, et al. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007;30:2945-2950.

    Article  CAS  PubMed  Google Scholar 

  • Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol. 1994;5:252-257.

    Article  CAS  PubMed  Google Scholar 

  • Ooi EMM, Barrett PH, Chan DC, et al. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis. 2008a;197:139-146.

    Article  CAS  PubMed  Google Scholar 

  • Ooi EMM, Watts GF, Nestel PJ, et al. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab. 2008b;93:430-437.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-318.

    Google Scholar 

  • Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265:568-580.

    Article  CAS  PubMed  Google Scholar 

  • Phan BAP, Dayspring TD, Tot PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-427.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.

    Article  PubMed  Google Scholar 

  • Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683-1701.

    Article  PubMed  Google Scholar 

  • Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol. 2000;11:3-7.

    Article  CAS  PubMed  Google Scholar 

  • Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-340.

    Article  CAS  PubMed  Google Scholar 

  • Rana JS, Visser ME, Arsenault BJ et al. Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Int J Cardiol. 2009;in press.

    Google Scholar 

  • Rashid S, Watanabe T, Sakaue T, et al. Mechanisms of HDL lowering in insulin resistant, hypertri-glyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36:421-429.

    Article  CAS  PubMed  Google Scholar 

  • Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170:1024-1031.

    Article  CAS  PubMed  Google Scholar 

  • Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.

    Article  PubMed  Google Scholar 

  • Riches FM, Watts GF, Hua J, et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999;84:2854-2861.

    CAS  PubMed  Google Scholar 

  • Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800-1808.

    Google Scholar 

  • Rizzo M, Rini GB, Spinas GA, et al. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis. 2009;204:330-333.

    Article  CAS  PubMed  Google Scholar 

  • Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.

    Article  CAS  PubMed  Google Scholar 

  • Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509.

    Article  CAS  PubMed  Google Scholar 

  • Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;12(363):692-694.

    Google Scholar 

  • Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care. 2009;32:493-498.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-241.

    Article  CAS  PubMed  Google Scholar 

  • Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-798.

    Article  CAS  PubMed  Google Scholar 

  • Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb Vasc Biol. 1993;13:629-636.

    Article  CAS  Google Scholar 

  • Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.

    Article  CAS  PubMed  Google Scholar 

  • Stein EA, Raal FJ. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014;43:1007-1033.

    Article  PubMed  Google Scholar 

  • Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-69B.

    Article  CAS  PubMed  Google Scholar 

  • Stolinski M, Alam S, Jackson NC, et al. Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus. Metabolism. 2008;57:608-614.

    Article  CAS  Google Scholar 

  • Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-S45.

    Article  PubMed  Google Scholar 

  • Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-1844.

    Article  CAS  PubMed  Google Scholar 

  • Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-749.

    Article  PubMed  Google Scholar 

  • Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertri-glyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:12144-12150.

    Article  CAS  Google Scholar 

  • Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359-404.

    Article  CAS  PubMed  Google Scholar 

  • The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.

    Article  PubMed Central  Google Scholar 

  • The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.

    Article  CAS  Google Scholar 

  • The Coronory Drug Project Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.

    Article  Google Scholar 

  • Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.

    Google Scholar 

  • Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk : a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178-2184.

    Article  CAS  PubMed  Google Scholar 

  • Thompson GR, Naoumova R, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37:439-447.

    CAS  PubMed  Google Scholar 

  • Thompson PD, Yurgalevitch SM, Flynn MM, et al. Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. Metabolism. 1997;46:217-223.

    Article  CAS  PubMed  Google Scholar 

  • Tremblay AJ, Lamarche B, Cohn JS, et al. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men With primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:1101-1106.

    Article  CAS  PubMed  Google Scholar 

  • Tsekouras YE, Magkos F, Prentzas KI, et al. A single bout of whole-body resistance exercise augments basal VLDL-triacylglycerol removal from plasma in healthy untrained men. Clin Sci. 2009;116:147-156.

    Article  CAS  PubMed  Google Scholar 

  • Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006;4:107-110.

    Article  CAS  PubMed  Google Scholar 

  • van der Hoorn JWA, de Haan W, Berbee JFP, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol. 2008;28:2016-2022.

    Article  PubMed  CAS  Google Scholar 

  • van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634-642.

    Article  PubMed  CAS  Google Scholar 

  • Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord. 1997;21:S5-S9.

    PubMed  Google Scholar 

  • Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-436.

    Article  CAS  PubMed  Google Scholar 

  • Watts GF, Chan DC, Barrett PH, et al. Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men. Obes Res. 2003a;11:152-159.

    Article  PubMed  Google Scholar 

  • Watts GF, Chan DC, Barrett PH, et al. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord. 2003b;27:862-865.

    Article  CAS  PubMed  Google Scholar 

  • Watts GF, Barrett PHR, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003c;52:803-811.

    Article  CAS  PubMed  Google Scholar 

  • Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10:648-661.

    Article  CAS  PubMed  Google Scholar 

  • Westheim A, Os I. Physical activity and the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol. 1992;20:S49-S53.

    Article  PubMed  Google Scholar 

  • Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481-1486.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wong AT, Chan DC, Pang J, et al. Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab. 2014a;99:E122-E126.

    Article  PubMed  Google Scholar 

  • Wong AT, Chan DC, Barrett PH, et al. Effect of o-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab. 2014b;99:E1427-E1435.

    Article  CAS  PubMed  Google Scholar 

  • Xu J, Nakamura MT, Cho HP, et al. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem. 1999;274:23577-23583.

    Article  CAS  PubMed  Google Scholar 

  • Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990;82:1574-1594.

    Article  CAS  PubMed  Google Scholar 

  • Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937-952.

    Article  PubMed  Google Scholar 

  • Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640-1649.

    Article  PubMed  Google Scholar 

  • Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res. 2007;48:1673-1680.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

DCC is a Career Development Fellow of NHMRC.

Author information

Authors and Affiliations

  1. Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, GPO Box X2213, Perth, WA, 6847, Australia

    Dick C. Chan, Jing Pang & Gerald F. Watts

  2. Lipid Disorders Clinic Royal Perth Hospital School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia

    Gerald F. Watts

Authors
  1. Dick C. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerald F. Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald F. Watts .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Rexford S. Ahima

  2. Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA, USA

    Rexford S. Ahima

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this entry

Cite this entry

Chan, D.C., Pang, J., Watts, G.F. (2016). Dyslipidemia in Obesity. In: Ahima, R.S. (eds) Metabolic Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-11251-0_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-11251-0_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-11250-3

  • Online ISBN: 978-3-319-11251-0

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation